4//SEC Filing
Jacobs Bruce N. 4
Accession 0000950170-23-025989
CIK 0001815442other
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 2:17 PM ET
Size
6.8 KB
Accession
0000950170-23-025989
Insider Transaction Report
Form 4
Jacobs Bruce N.
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-06-02+10,000→ 129,899 totalExercise: $2.08Exp: 2029-08-28→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2023-06-02$2.08/sh+10,000$20,800→ 115,035 total
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001821074
Filing Metadata
- Form type
- 4
- Filed
- Jun 1, 8:00 PM ET
- Accepted
- Jun 2, 2:17 PM ET
- Size
- 6.8 KB